Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Performance-Based Conditions Could Ease Post-Approval Changes For Process Analytical Technologies, Experts Say

Executive Summary

Pharmaceutical industry officials are promoting the idea of “marrying” the concepts of performance-based approaches and process analytical technology in the draft ICH Q12 guideline. Embedding this idea in ICH Q12 would give industry more flexibility in managing post-approval changes and aligns with the guideline’s concept of lifecycle improvement.

Advertisement

Related Content

Gottlieb: Valsartan API Crisis Spurs Drug GMP Revision
Pharma Sector Explores How To Embrace The Fourth Industrial Revolution
FDA And Industry Officials Tout Benefits Of Performance-Based Established Conditions In ICH Q12
Vertex Eyes Triple Glory After Hat Trick of CF Approvals
Global Post-Approval Changes Outlook Murky As Q12 Lurches Into Consultation
FDA Suggests Preoperational Review Meetings Before Submitting NDAs For Continuous Manufacturing

Topics

Advertisement
UsernamePublicRestriction

Register

PS124903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel